[{"id":"9f5673ee-f7a4-40b1-ace8-59a97f2bd04f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01990196","created_at":"2021-01-18T09:04:40.027Z","updated_at":"2025-02-25T13:10:58.081Z","phase":"Phase 2","brief_title":"Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer","source_id_and_acronym":"NCT01990196","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" VIM • CDH2","pipe":" | ","alterations":" VIM expression","tags":["VIM • CDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VIM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • dasatinib • Xtandi (enzalutamide) • Firmagon (degarelix)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/23/2014","start_date":" 09/23/2014","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-10-01"},{"id":"92a218df-d6c0-44fe-8a39-9c050b9e66de","acronym":"","url":"https://clinicaltrials.gov/study/NCT05550415","created_at":"2022-09-22T13:55:23.932Z","updated_at":"2024-07-02T16:36:03.476Z","phase":"Phase 2","brief_title":"The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer","source_id_and_acronym":"NCT05550415","lead_sponsor":"Indonesia University","biomarkers":" VIM","pipe":" | ","alterations":" VIM expression","tags":["VIM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VIM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 08/19/2022","start_date":" 08/19/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2022-09-26"},{"id":"6444be69-5df8-4e85-ac83-3168d655efd8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00897533","created_at":"2021-01-18T03:26:36.159Z","updated_at":"2024-07-02T16:37:21.937Z","phase":"","brief_title":"Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00897533","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" CDH1 • VIM","pipe":" | ","alterations":" VIM expression","tags":["CDH1 • VIM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VIM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Completed","enrollment":" Enrollment 137","initiation":"Initiation: 04/13/2007","start_date":" 04/13/2007","primary_txt":" Primary completion: 04/13/2008","primary_completion_date":" 04/13/2008","study_txt":" Completion: 04/13/2008","study_completion_date":" 04/13/2008","last_update_posted":"2017-05-19"}]